On January 5, 2023 Invectys, Inc. "Invectys", a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of cell therapy products for cancer patients, reported that Praveen Tyle, Ph.D., President and CEO of Invectys, will participate in the 2023 edition of the JP Morgan Healthcare Meeting on January 9-12, 2023 (Press release, Invectys, JAN 5, 2023, View Source [SID1234625901]). In addition to the main meeting, Dr. Tyle will also attend the 2023 BIO One-on-One partnering meetings live from January 9-12 at the San Francisco Marriott Marquis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!